These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 28416551

  • 1. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
    Lepak AJ, Zhao M, Andes DR.
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC, Okusanya ÓO, Lakota EA, Forrest A, Bhavnani SM, Hoover JL, Andes DR, Ambrose PG.
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [Abstract] [Full Text] [Related]

  • 4. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
    Lepak AJ, Marchillo K, Craig WA, Andes DR.
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.
    Hegde SS, Okusanya OO, Skinner R, Shaw JP, Obedencio G, Ambrose PG, Blais J, Bhavnani SM.
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1578-83. PubMed ID: 22155835
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
    Lepak AJ, Andes DR.
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
    Hegde SS, Reyes N, Wiens T, Vanasse N, Skinner R, McCullough J, Kaniga K, Pace J, Thomas R, Shaw JP, Obedencio G, Judice JK.
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
    Andes D, Craig WA.
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
    Hoover J, Lewandowski T, Straub RJ, Novick SJ, DeMarsh P, Aubart K, Rittenhouse S, Zalacain M.
    Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Lubenko IY, Strukova EV, Smirnova MV, Vostrov SN, Portnoy YA, Zinner SH, Firsov AA.
    J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
    Crandon JL, Banevicius MA, Nicolau DP.
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1165-9. PubMed ID: 19114676
    [Abstract] [Full Text] [Related]

  • 16. In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model.
    Lepak AJ, Parhi A, Madison M, Marchillo K, VanHecker J, Andes DR.
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6568-74. PubMed ID: 26259789
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
    Hegde SS, Difuntorum S, Skinner R, Trumbull J, Krause KM.
    J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
    [Abstract] [Full Text] [Related]

  • 18. Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
    Al Jalali V, Zeitlinger M.
    Clin Pharmacokinet; 2018 Jul; 57(7):797-816. PubMed ID: 29332251
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.
    Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR.
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.